ELV241220C500000
- 0.05
- 0.000.00%
Elevance Health Newsroom
Barclays Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $501
Barclays Remains a Buy on Elevance Health (ELV)
Bernstein Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $502
Analysts Conflicted on These Healthcare Names: Elevance Health (ELV), Agilent (A) and Insulet (PODD)
Elevance Health Is Maintained at Buy by Truist Securities
Truist Financial Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $480
Elevance Health Analyst Ratings
Truist Securities Maintains Buy on Elevance Health, Lowers Price Target to $480
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $455
Mizuho Adjusts Price Target on Elevance Health to $455 From $505, Keeps Outperform Rating
Elevance Health Downgraded to Equal Weight From Overweight at Morgan Stanley
Morgan Stanley Downgrades Elevance Health(ELV.US) to Hold Rating, Cuts Target Price to $388
Morgan Stanley Sticks to Its Buy Rating for Elevance Health (ELV)
Jefferies Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $458
Wells Fargo Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $483
Wells Fargo Adjusts Price Target on Elevance Health to $483 From $495, Maintains Overweight Rating
Wells Fargo Reaffirms Their Buy Rating on Elevance Health (ELV)
Elevance Health Price Target Cut to $505.00/Share From $585.00 by Mizuho
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating, Announces Target Price $505
Elevance Health Is Maintained at Overweight by Wells Fargo